Filing Details

Accession Number:
0001209191-19-041298
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-03 20:00:44
Reporting Period:
2019-07-01
Accepted Time:
2019-07-03 20:00:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
897448 Amarin Corp Plc AMRN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1678248 Wayne Michael Kalb C/O Amarin Pharma, Inc.
1430 Route 206
Bedminster NJ 07921
Svp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-07-01 50,000 $2.19 70,840 No 4 M Direct
Ordinary Shares Disposition 2019-07-01 50,000 $19.67 20,840 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2019-07-01 50,000 $0.00 50,000 $2.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
175,000 2026-07-01 No 4 M Direct
Footnotes
  1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  3. Please see the section titled "Remarks" below for additional information.
  4. Includes 289 shares purchased under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2019.
  5. On July 1, 2016, the Reporting Person was granted an option to purchase 625,000 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The shares subject to this option shall vest as follows: 25% of the total number of underlying shares shall vest on July 1, 2017, and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months.